PMID- 24562476
OWN - NLM
STAT- MEDLINE
DCOM- 20141201
LR  - 20151119
IS  - 1753-9455 (Electronic)
IS  - 1753-9447 (Linking)
VI  - 8
IP  - 2
DP  - 2014 Apr
TI  - Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or 
      amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with 
      hypertension from Pakistan.
PG  - 45-55
LID - 10.1177/1753944714525496 [doi]
AB  - OBJECTIVE: EXCITE (clinical EXperienCe of amlodIpine and valsarTan in 
      hypErtension) evaluated the real-life effectiveness, safety, and tolerability of 
      single-pill combinations (SPCs) of amlodipine/valsartan (Aml/Val) and 
      amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) in patients with 
      hypertension from 13 countries in the Middle East and Asia. Here, we present data 
      from Pakistan. METHODS: This was a 26-week observational, multicenter, 
      prospective, open-label study. At week 26, change from baseline in mean sitting 
      systolic (msSBP) and diastolic blood pressure (msDBP) and the proportion of 
      patients achieving BP goal (SBP/DBP <140/90 mmHg; <130/80 mmHg in patients with 
      diabetes) and response rates (SBP <140 mmHg [130 mmHg for patients with diabetes] 
      or reduction of >/=20 mmHg; DBP <90 mmHg [80 mmHg for patients with diabetes] or 
      reduction of >/=10 mmHg), were evaluated. Incidence of adverse events (AEs) and 
      serious AEs (SAEs) was recorded as safety variables. Subjective assessment of 
      effectiveness, compliance and tolerability was done by the physician. RESULTS: A 
      total of 500 patients with hypertension (mean age of 48 years) were prescribed 
      Aml/Val (n = 471, 94%) or Aml/Val/HCTZ (n = 29, 6%); 439 (87.8%) patients 
      completed the study. At week 26, the mean BP decreased from 153.4/91.1 mmHg at 
      baseline to 128.9/78.4 mmHg in the Aml/Val cohort (-24.5/-12.7 mmHg; p < 0.0001) 
      and from 171.6/99.3 mmHg at baseline to 127.7/77.4 mmHg (-43.9/-21.9 mmHg; p < 
      0.0001) in the Aml/Val/HCTZ cohort. BP goals were achieved by 57% and 55.2% of 
      patients in the Aml/Val and Aml/Val/HCTZ cohorts, respectively. A total of 40 
      (8%) patients reported at least one AE during the study period. Most common AEs 
      included nausea (1.6%), headache (1.2%), vomiting (1.2%), and edema (1.2%). Most 
      patients in Aml/Val cohort and all patients in Aml/Val/HCTZ cohort rated the 
      effectiveness, compliance and tolerability as 'good' or 'very good'. CONCLUSIONS: 
      Aml/Val with or without HCTZ in a SPC was effective and well-tolerated for BP 
      reduction in this cohort of patients with hypertension from Pakistan.
FAU - Khan, Waheed
AU  - Khan W
AD  - Adil Hospital Lahore, Lahore, Pakistan.
FAU - Moin, Nasir
AU  - Moin N
FAU - Iktidar, Somia
AU  - Iktidar S
FAU - Sakrani, Javed
AU  - Sakrani J
FAU - Abid, Rizwan
AU  - Abid R
FAU - Afzal, Javed
AU  - Afzal J
FAU - Maheshwary, Neeta
AU  - Maheshwary N
FAU - Kumar, Kishore
AU  - Kumar K
FAU - Siddiqi, Ahson
AU  - Siddiqi A
FAU - Qadir, Murad
AU  - Qadir M
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140220
PL  - England
TA  - Ther Adv Cardiovasc Dis
JT  - Therapeutic advances in cardiovascular disease
JID - 101316343
RN  - 0 (Amlodipine, Valsartan Drug Combination)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Tetrazoles)
RN  - 0J48LPH2TH (Hydrochlorothiazide)
RN  - 1J444QC288 (Amlodipine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Amlodipine/adverse effects/*therapeutic use
MH  - Amlodipine, Valsartan Drug Combination
MH  - Antihypertensive Agents/adverse effects/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Hydrochlorothiazide/*administration & dosage/adverse effects
MH  - Hypertension/*drug therapy/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Tetrazoles/adverse effects/*therapeutic use
OTO - NOTNLM
OT  - amlodipine
OT  - angiotensin receptor blocker
OT  - calcium channel blocker
OT  - diastolic blood pressure
OT  - hydrochlorothiazide
OT  - hypertension
OT  - systolic blood pressure
OT  - valsartan
EDAT- 2014/02/25 06:00
MHDA- 2014/12/15 06:00
CRDT- 2014/02/25 06:00
PHST- 2014/02/25 06:00 [entrez]
PHST- 2014/02/25 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - 1753944714525496 [pii]
AID - 10.1177/1753944714525496 [doi]
PST - ppublish
SO  - Ther Adv Cardiovasc Dis. 2014 Apr;8(2):45-55. doi: 10.1177/1753944714525496. Epub 
      2014 Feb 20.